Payer / HTA meeting · Dr. Sven Fischer

30 Apr 2026 · Virtual · Dr. Sven Fischer, Hôpital Pitié-Salpêtrière · MSL Rachel Adeyemi · Vantrexa

ReviewedManualENG-0001—

Capture insight from this engagement

Location: Hôpital Pitié-Salpêtrière
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Brain-metastasis subgroup data

Scientific content used

VTX core scientific deck v3.2
irAE management guide

Questions raised

Is there subgroup data for patients with untreated brain metastases?
How should grade 2 infusion reactions be managed without steroids?

Notes

Payer / HTA meeting with thoracic medical oncologist at Hôpital Pitié-Salpêtrière. Discussed elderly / ecog 2 patients, brain-metastasis subgroup data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 1
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0001

Audit history (0)

All create, update and approval events for this record

No audit events in sample data